Ampio Pharmaceuticals Inc
(NASDAQ: AMPE)
+0.03
+0.60%
| Exchange: | NASDAQ |
| Stock: | Ampio Pharmaceuticals Inc |
| Industry: | NA |
| Employees: | 13 |
| Ampio Pharmaceuticals, Inc. (Ampio) is a development-stage biopharmaceutical company focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company is primarily focused on providing medicines to improve the health and quality of life of patients with minimal side effects. Ampio is engaged in developing pharmaceutical drugs and diagnostic products to identify, treat and prevent a range of human diseases, including metabolic disorders, eye disease, kidney disease, acute and chronic inflammation diseases and male sexual dysfunction. The Company is also focused on monetizing its sexual dysfunction portfolio and a diagnostic device. In February 2013, it announced the incorporation and initiation of operations of Luoxis Diagnostics. |
Copyright © 2013 Microsoft. All rights reserved.
Quotes are real-time for NASDAQ, NYSE and AMEX. See delay times for other exchanges.
Fundamental company data and historical chart data provided by Thomson Reuters (click for restrictions). Real-time quotes provided by BATS Exchange. Real-time index quotes and delayed quotes supplied by Interactive Data Real-Time Services. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations data provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by SIX Financial Information.
Japanese stock price data provided by Nomura Research Institute Ltd.; quotes delayed 20 minutes. Canadian fund data provided by CANNEX Financial Exchanges Ltd.
